샘플 요청 목록

 카트 문의
시장보고서
상품코드
1654378

패혈증 진단 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 기술별, 병원체별, 검사별, 방법별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Sepsis Diagnostics Market Size, Share & Trends Analysis Report By Product, By Technology, By Pathogen, By Testing, By Method, By End-usse, By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

패혈증 진단 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 패혈증 진단 시장 규모는 2030년까지 18억 2,000만 달러에 달할 것으로 예상되며 2025년부터 2030년까지 8.09%의 CAGR을 기록할 것으로 전망됩니다. 패혈증의 높은 유병률, 기술적으로 진보된 진단 시스템의 도입, 정부 이니셔티브의 증가는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 패혈증은 혈액에 존재하는 병원성 미생물에 대한 반응의 결과로 발생하는 혈류 질환입니다. 이 질병을 앓고 있는 환자는 심각한 염증을 경험하여 장기 입원으로 이어집니다.

세계보건기구에 따르면 매년 약 3천만 명이 이 질병의 영향을 받는 것으로 추정됩니다. NCBI는 이 질환의 가장 많은 수가 최연소 및 최고령 그룹에서 관찰되었다고 밝혔습니다. 따라서이 질병의 조기 진단에 대한 필요성이 증가하고 있습니다. WHO는 매년 전 세계적으로 120만 명의 어린이와 300만 명의 신생아가 이 질병의 영향을 받는다고 보고했습니다. 이로 인해 빠른 결과와 개선된 환자 예후를 위한 진단 도구에 대한 수요가 더욱 증가하고 있습니다. 패혈증에 대한 규제 승인 증가와 기술적으로 진보된 진단 솔루션의 도입은 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

2018년 5월, 미국에 본사를 둔 신생 진단 솔루션 회사인 T2 바이오시스템즈(T2 Biosystems, Inc.)는 인간 전혈 표본에서 특정 패혈증을 유발하는 박테리아 병원균을 검출하기 위한 T2Bacteria Panel에 대한 미국 FDA의 승인을 받았습니다. 코로나19 팬데믹은 패혈증 진단 제품의 성장에 다소 긍정적인 영향을 미쳤습니다. 코로나19가 전 세계적으로 확산되고 코로나19 환자들 사이에서 패혈증 사례가 발생하면서 패혈증을 빠르게 감지할 수 있는 기기, 시약, 분석 키트에 대한 관심이 확대될 것으로 보입니다. 팬데믹으로 인한 봉쇄 및 기타 제한 조치로 인해 개인이 건강 검진을 미루면서 검사 횟수 및 시약 거래에 영향을 미쳤습니다.

팬데믹으로 인해 일반적으로 패혈증 발생 위험을 높이는 폐렴으로 인한 중증 호흡곤란 상태를 비롯한 합병증에 더 취약한 노년층이 위험에 노출되었습니다. 따라서 코로나19 환자의 패혈증 조기 발견에 대한 필요성이 대두되고 있습니다. 세계의 패혈증 연합의 추정에 따르면 다기관 손상과 같은 패혈증 증상은 입원 후 8-10일 후에 코로나19 사례의 약 2.0-5.0%에서 발생합니다. 이러한 상황을 관리하기 위해 2020년 5월, 바이오메디컬 첨단 연구 개발 당국은 코로나19 환자의 패혈증을 감지하는 디지털 알고리즘 개발을 위해 베크만 콜터와 파트너십을 연장했습니다.

패혈증 진단 시장 보고서 하이라이트

  • 제품별로는 혈액 배양이 가장 비용 효율적이고 편리한 검사 방식으로 간주되기 때문에 혈액 배양 배지가 2024년 38.90% 이상의 매출 점유율로 시장을 지배했습니다.
  • 미생물학 기술 부문은 2024년 세계의 시장을 지배하며 전체 매출의 48.77% 이상을 차지하며 가장 큰 비중을 차지했습니다.
  • 박테리아 부문은 2024년에 86.22%의 가장 큰 매출 점유율을 차지했으며 세균성 패혈증 사례 증가, 병원 매개 감염 발생 증가, 수술 시행 건수 증가로 인해 예측 기간 동안 선두를 유지할 것으로 예상됩니다.
  • 기존 진단 부문은 2024년 패혈증 진단 산업에서 57.12%의 가장 큰 매출 점유율을 차지했습니다.
  • 병원 및 클리닉 부문은 입원의 증가로 인해 2024년에 79.42%의 가장 큰 매출 점유율을 차지했습니다.
  • 실험실 검사 부문은 2024년 매출 점유율 측면에서 시장을 지배했습니다. 실험실 검사의 발전으로 패혈증을 더 쉽고 빠르게 발견할 수 있게 되어 환자에게 더 나은 결과를 가져다주었습니다.
  • 북미의 패혈증 진단 시장은 2024년 전 세계에서 가장 큰 매출 점유율을 차지하며 43.9% 이상의 점유율을 차지했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 패혈증 진단 시장의 변수, 동향, 범위

  • 시장 계통의 전망
    • 상위 시장 전망
    • 관련 및 보조시장 전망
  • 시장 역학
    • 시장 성장 촉진요인의 영향 분석
    • 시장 성장 억제요인 분석
    • 산업의 과제
  • 패혈증 진단 : 시장 분석 도구
    • Porter's Five Forces 분석
    • 패혈증 진단 - 거시 경제 분석

제4장 패혈증 진단 시장 : 부문 분석, 제품별(2018-2030년)

  • 패혈증 진단 시장 : 제품 변동 분석
  • 제품별

제5장 패혈증 진단 시장 : 부문 분석, 기술별(2018-2030년)

  • 패혈증 진단 시장 : 기술 변동 분석
  • 기술별

제6장 패혈증 진단 시장 : 부문 분석, 병원체별(2018-2030년)

  • 패혈증 진단 시장 : 병원체 변동 분석
  • 병원체별

제7장 패혈증 진단 시장 : 부문 분석, 검사별(2018-2030년)

  • 패혈증 진단 시장 : 검사 변동 분석
  • 검사별

제8장 패혈증 진단 시장 : 부문 분석, 방법별(2018-2030년)

  • 패혈증 진단 시장 : 방법 변동 분석
  • 방법별

제9장 패혈증 진단 시장 : 부문 분석, 최종 용도별(2018-2030년)

  • 패혈증 진단 시장 : 최종 용도 변동 분석
  • 최종 용도별

제10장 패혈증 진단 시장 : 지역 추정 및 동향 분석, 제품별, 기술별, 병원체별, 검사별, 방법별, 최종 용도별

  • 패혈증 진단 시장 : 지역별 전망
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 스페인
    • 이탈리아
    • 덴마크
    • 스웨덴
    • 노르웨이
    • 러시아
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 태국
    • 한국
    • 싱가포르
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제11장 경쟁 구도

  • 기업 분류
  • 기업의 시장 포지셔닝
    • 마켓 리더
  • 기업 프로파일
    • Biomerieux Sa
    • Becton, Dickinson And Company(Bd)
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche
    • Luminex Corporation
    • Danaher
    • Luminex Corporation
    • Bruker Corporation
    • Amara Health Analytics
    • Cepheid
    • Beckman Coulter, Inc.
    • Bruker Corporation
    • Immunexpress, Inc.
    • Koninklijke Philips NV
HBR 25.03.06

Sepsis Diagnostics Market Growth & Trends:

The global sepsis diagnostics market size is expected to reach USD 1.82 billion by 2030, registering a CAGR of 8.09% from 2025 to 2030, according to a new report by Grand View Research, Inc. The high prevalence of sepsis, the introduction of technologically advanced diagnostic systems, and increasing government initiatives are expected to propel market growth over the forecast period. Sepsis is a bloodstream disease that occurs as a result of a response to pathogenic microorganisms present in the blood. Patients suffering from this disease experience severe inflammation, which leads to prolonged hospitalization.

According to the WHO, around 30 million people are estimated to be affected by this disease every year. The NCBI stated that the largest number of this condition have been observed in the youngest and oldest age groups. Thus, there is a rising need for the early diagnosis of this disease. The WHO reported that every year, 1.2 million children and 3 million newborns are affected by this disease across the world. This has further boosted the demand for its diagnostic tools for quick results and improved patient outcomes. Increasing regulatory approval and the introduction of technologically advanced diagnostic solutions for sepsis are expected to facilitate market growth over the forecast period.

In May 2018, T2 Biosystems, Inc., a U.S.-based emerging diagnostic solutions company, received the U.S. FDA approval for its T2Bacteria Panel, intended for the detection of specific sepsis-causing bacterial pathogens in human whole blood specimens. The COVID-19 pandemic affected the growth of diagnostics products for sepsis in a moderately positive way. The worldwide spread of Coronavirus and the arising instances of sepsis among COVID-19 patients are probably going to expand the interest for fast detection, speeding up the use of instruments, reagents, and assay kits for recognition of sepsis. Pandemic-induced lockdown and other restrictions made individuals delay going through wellbeing checkups, influencing the number of tests performed and reagent deals.

The pandemic has featured the risk upon elders, who are more defenseless to complications, including intense respiratory distress condition, typically because of pneumonia, which builds the risk of creating sepsis. This has created a need for the early detection of sepsis among patients with COVID-19. Symptoms of sepsis, such as multiorgan injuries, develop in around 2.0 to 5.0% of COVID-19 cases 8 to 10 days post-hospitalization, based on the estimates of the Global Sepsis Alliance. To manage this situation, the Biomedical Advanced Research and Development Authority, in May 2020, extended its partnership with Beckman Coulter for the development of a digital algorithm to detect sepsis in patients with COVID-19.

Sepsis Diagnostics Market Report Highlights:

  • Based on product, blood culture media dominated the market in 2024 with a revenue share of more than 38.90%, as blood culture is considered to be the most cost-effective and convenient mode of testing.
  • The microbiology technology segment dominated the global market in 2024 and accounted for the largest share of more than 48.77% of the overall revenue.
  • Bacterial segment held the largest revenue share of 86.22% in 2024 and is anticipated to maintain its lead over the forecast period owing to the rise in cases of bacterial sepsis, higher occurrence of hospital-transmitted infections, and rising number of surgical procedures conducted.
  • The conventional diagnostics segment held the largest revenue share of 57.12% of the sepsis diagnostics industry in 2024.
  • The hospital and clinics segment held the largest revenue share of 79.42% in 2024, owing to an increase in hospitalization.
  • The laboratory testing segment dominated the market in 2024 in terms of revenue share. Advancements in laboratory testing have made it easier and faster to detect sepsis, leading to better outcomes for patients.
  • North America sepsis diagnostics market dominated globally in 2024 and accounted for the largest revenue share of more than 43.9%.

Table Of Contents

Chapter 1 Methodology And Scope

  • 1.1 Market Segmentation And Scope
  • 1.2 Market Definitions
    • 1.2.1 Estimates And Forecast Timeline
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database:
    • 1.4.2 Gvr's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
    • 1.4.5 Details Of Primary Research
  • 1.5 Information Or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach: Commodity Flow Approach
  • 1.8 Research Assumptions
  • 1.9 List Of Secondary Sources
  • 1.10 List Of Abbreviations
  • 1.11 Objectives
    • 1.11.1 Objective 1
    • 1.11.2 Objective 2
    • 1.11.4 Objective 3
    • 1.11.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Product And Technology Snapshot
  • 2.3 Pathogen And Testing Snapshot
  • 2.4 Method And End Use Snapshot
  • 2.5 Competitive Landscape Snapshot

Chapter 3 Sepsis Diagnostics Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Related/Ancillary Market Outlook
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Impact Analysis
      • 3.2.1.1 Increase In Prevalence Of Sepsis
      • 3.2.1.2 Rise In Incidence Of Hospital-Acquired Infections
      • 3.2.1.3 Increase In The Number Of Pneumonia Cases
      • 3.2.1.4 Approval And Launch Of Advanced Sepsis Diagnostic System
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 High Cost Of Automated Diagnostic Instruments
      • 3.2.2.2 Lack Of Awareness About Sepsis
    • 3.2.3 Industry Challenges
      • 3.2.3.1 Scientific And Clinical Challenges Associated With Sepsis
  • 3.3 Sepsis Diagnostics: Market Analysis Tools
    • 3.3.1 Porter's Analysis
    • 3.3.2 Sepsis Diagnostics - Macroeconomic Analysis

Chapter 4 Sepsis Diagnostics Market: Segment Analysis, By Product, 2018 - 2030 (USD Million)

  • 4.1 Sepsis Diagnostics Market: Product Movement Analysis
  • 4.2 Sepsis Diagnostics Market Estimates & Forecast, By Product (USD Million)
    • 4.2.1 Instrument
    • 4.2.2 Blood Culture Media
    • 4.2.3 Assay Kits And Reagents
    • 4.2.4 Software

Chapter 5 Sepsis Diagnostics Market: Segment Analysis, By Technology, 2018 - 2030 (USD Million)

  • 5.1 Sepsis Diagnostics Market: Technology Movement Analysis
  • 5.2 Sepsis Diagnostics Market Estimates & Forecast, By Technology (USD Million)
    • 5.2.1 Microbiology
    • 5.2.2 Molecular Diagnostics
      • 5.2.2.1 Polymerase Chain Reaction (Pcr)
      • 5.2.2.2 Dna Microarrays
      • 5.2.2.3 Syndromic Panel Testing
      • 5.2.2.4 Others
    • 5.2.3 Immunoassays
    • 5.2.4 Flow Cytometry
    • 5.2.5 Others

Chapter 6 Sepsis Diagnostics Market: Segment Analysis, By Pathogen, 2018 - 2030 (USD Million)

  • 6.1 Sepsis Diagnostics Market: Pathogen Movement Analysis
  • 6.2 Sepsis Diagnostics Market Estimates & Forecast, By Pathogen (USD Million)
    • 6.2.1 Bacterial Sepsis
      • 6.2.1.1 Gram-Positive Bacteria
      • 6.2.1.2 Gram-Negative Bacteria
    • 6.2.2 Fungal Sepsis
    • 6.2.3 Viral Sepsis
    • 6.2.4 Others

Chapter 7 Sepsis Diagnostics Market: Segment Analysis, By Testing, 2018 - 2030 (USD Million)

  • 7.1 Sepsis Diagnostics Market: Testing Movement Analysis
  • 7.2 Sepsis Diagnostics Market Estimates & Forecast, By Testing (USD Million)
    • 7.2.1 Laboratory Testing
    • 7.2.2 Point-Of-Care Testing

Chapter 8 Sepsis Diagnostics Market: Segment Analysis, By Method, 2018 - 2030 (USD Million)

  • 8.1 Sepsis Diagnostics Market: Method Movement Analysis
  • 8.2 Sepsis Diagnostics Market Estimates & Forecast, By Method (USD Million)
    • 8.2.1 Automated Diagnostics
    • 8.2.2 Conventional Diagnostics

Chapter 9 Sepsis Diagnostics Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)

  • 9.1 Sepsis Diagnostics Market: End Use Movement Analysis
  • 9.2 Sepsis Diagnostics Market Estimates & Forecast, By End Use (USD Million)
    • 9.2.1 Hospitals & Clinics
    • 9.2.2 Pathology & Reference Laboratories
    • 9.2.3 Research Institutes And Others

Chapter 10 Sepsis Diagnostic Market: Regional Estimates And Trend Analysis, By Product, By Technology, By Pathogen, By Testing, By Method, & By End Use

  • 10.1 Sepsis Diagnostic Market: Regional Outlook
  • 10.2 North America
    • 10.2.1 North America Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.2.1.1 Regulatory Framework
      • 10.2.1.2 Reimbursement Scenario
    • 10.2.2 U.S.
      • 10.2.2.1 Key Country Dynamics
      • 10.2.2.2 U.S. Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.2.2.3 Market & Competitive Scenario
    • 10.2.3 Canada
      • 10.2.3.1 Key Country Dynamics
      • 10.2.3.2 Canada Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.2.3.3 Market And Competitive Scenario
  • 10.3 Europe
    • 10.3.1 Europe Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.3.1.1 Regulatory Framework
      • 10.3.1.2 Reimbursement Scenario
    • 10.3.2 Uk
      • 10.3.2.1 Key Country Dynamics
      • 10.3.2.2 Uk Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.3.2.3 Market & Competitive Scenario
    • 10.3.3 Germany
      • 10.3.3.1 Key Country Dynamics
      • 10.3.3.2 Germany Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.3.3.3 Market & Competitive Scenario
    • 10.3.4 France
      • 10.3.4.1 Key Country Dynamics
      • 10.3.4.2 France Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.3.4.3 Market & Competitive Scenario
    • 10.3.5 Spain
      • 10.3.5.1 Key Country Dynamics
      • 10.3.5.2 Spain Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.3.5.3 Market & Competitive Scenario
    • 10.3.6 Italy
      • 10.3.6.1 Key Country Dynamics
      • 10.3.6.2 Italy Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.3.6.3 Market & Competitive Scenario
    • 10.3.7 Denmark
      • 10.3.7.1 Key Country Dynamics
      • 10.3.7.2 Denmark Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.3.7.3 Market & Competitive Scenario
    • 10.3.8 Sweden
      • 10.3.8.1 Key Country Dynamics
      • 10.3.8.2 Sweden Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.3.8.3 Market & Competitive Scenario
    • 10.3.9 Norway
      • 10.3.9.1 Key Country Dynamics
      • 10.3.9.2 Norway Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.3.9.3 Market & Competitive Scenario
    • 10.3.10 Russia
      • 10.3.10.1 Key Country Dynamics
      • 10.3.10.2 Russia Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.3.10.3 Market & Competitive Scenario
      • 10.3.10.4 Rest Of Europe Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 10.4 Asia Pacific
    • 10.4.1 Asia Pacific Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.4.1.1 Regulatory Framework
      • 10.4.1.2 Reimbursement Scenario
    • 10.4.2 Japan
      • 10.4.2.1 Key Country Dynamics
      • 10.4.2.2 Japan Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.4.2.3 Market And Competitive Scenario
    • 10.4.3 China
      • 10.4.3.1 Key Country Dynamics
      • 10.4.3.2 China Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.4.3.3 Market And Competitive Scenario
    • 10.4.4 India
      • 10.4.4.1 Key Country Dynamics
      • 10.4.4.2 India Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.4.4.3 Market And Competitive Scenario
    • 10.4.5 Australia
      • 10.4.5.1 Key Country Dynamics
      • 10.4.5.2 Australia Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.4.5.3 Market And Competitive Scenario
    • 10.4.6 Thailand
      • 10.4.6.1 Key Country Dynamics
      • 10.4.6.2 Thailand Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.4.6.3 Market And Competitive Scenario
    • 10.4.7 South Korea
      • 10.4.7.1 Key Country Dynamics
      • 10.4.7.2 South Korea Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.4.7.3 Market And Competitive Scenario
    • 10.4.8 Singapore
      • 10.4.8.1 Key Country Dynamics
      • 10.4.8.2 Singapore Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.4.8.3 Market And Competitive Scenario
      • 10.4.8.4 Rest Of Asia Pacific Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 10.5 Latin America
    • 10.5.1 Latin America Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.5.1.1 Regulatory Framework
      • 10.5.1.2 Reimbursement Scenario
    • 10.5.2 Brazil
      • 10.5.2.1 Key Country Dynamics
      • 10.5.2.2 Brazil Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.5.2.3 Market And Competitive Scenario
    • 10.5.3 Mexico
      • 10.5.3.1 Key Country Dynamics
      • 10.5.3.2 Mexico Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.5.3.3 Market And Competitive Scenario
    • 10.5.4 Argentina
      • 10.5.4.1 Key Country Dynamics
      • 10.5.4.2 Argentina Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.5.4.3 Market And Competitive Scenario
      • 10.5.4.4 Rest Of Latam Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 10.6 MEA
    • 10.6.1 MEA Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.6.1.1 Regulatory Framework
      • 10.6.1.2 Reimbursement Scenario
    • 10.6.2 South Africa
      • 10.6.2.1 Key Country Dynamics
      • 10.6.2.2 South Africa Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.6.2.3 Market And Competitive Scenario
    • 10.6.3 Saudi Arabia
      • 10.6.3.1 Key Country Dynamics
      • 10.6.3.2 Saudi Arabia Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.6.3.3 Market And Competitive Scenario
    • 10.6.4 UAE
      • 10.6.4.1 Key Country Dynamics
      • 10.6.4.2 UAE Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.6.4.3 Competitive Scenario
    • 10.6.5 Kuwait
      • 10.6.5.1 Key Country Dynamics
      • 10.6.5.2 Kuwait Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 10.6.5.3 Market And Competitive Scenario
      • 10.6.5.4 Rest Of MEA Sepsis Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 11 Competitive Landscape

  • 11.1 Company Categorization
  • 11.2 Company Market Positioning
    • 11.2.1 Market Leaders
      • 11.2.1.1 Sepsis Diagnostics Market Share Analysis, 2024
  • 11.4 Company Profiles
  • 11.4 Company Profiles
    • 11.4.1 Biomerieux Sa
      • 11.4.1.1 Company Overview
      • 11.4.1.2 Financial Performance
      • 11.4.1.3 Product Benchmarking
      • 11.4.1.4 Strategic Initiatives
    • 11.4.2 Becton, Dickinson And Company (Bd)
      • 11.4.2.1 Company Overview
      • 11.4.2.2 Financial Performance
      • 11.4.2.3 Product Benchmarking
      • 11.4.2.4 Strategic Initiatives
    • 11.4.3 Thermo Fisher Scientific, Inc.
      • 11.4.3.1 Company Overview
      • 11.4.3.2 Financial Performance
      • 11.4.3.3 Product Benchmarking
      • 11.4.3.4 Strategic Initiatives
    • 11.4.4 F. Hoffmann-La Roche
      • 11.4.4.1 Company Overview
      • 11.4.4.2 Financial Performance
      • 11.4.4.3 Product Benchmarking
      • 11.4.4.4 Strategic Initiatives
    • 11.4.5 Luminex Corporation
      • 11.4.5.1 Company Overview
      • 11.4.5.2 Financial Performance
      • 11.4.5.3 Product Benchmarking
      • 11.4.5.4 Strategic Initiatives
    • 11.4.6 Danaher
      • 11.4.6.1 Cepheid
        • 11.4.6.1.1 Company Overview
        • 11.4.6.1.2 Financial Performance
        • 11.4.6.1.3 Product Benchmarking
        • 11.4.6.1.4 Strategic Initiatives
      • 11.4.6.2 Beckman Coulter, Inc.
        • 11.4.6.2.1 Company Overview
        • 11.4.6.2.2 Financial Performance
        • 11.4.6.2.3 Product Benchmarking
        • 11.4.6.2.4 Strategic Initiatives
    • 11.4.7 Luminex Corporation
      • 11.4.7.1 Company Overview
      • 11.4.7.2 Financial Performance
      • 11.4.7.3 Product Benchmarking
      • 11.4.7.4 Strategic Initiatives
    • 11.4.8 Bruker Corporation
      • 11.4.8.1 Company Overview
      • 11.4.8.2 Financial Performance
      • 11.4.8.3 Product Benchmarking
      • 11.4.8.4 Strategic Initiatives
    • 11.4.9 Amara Health Analytics
      • 11.4.9.1 Company Overview
      • 11.4.9.2 Financial Performance
      • 11.4.9.3 Product Benchmarking
      • 11.4.9.4 Strategic Initiatives
    • 11.4.10 Cepheid
      • 11.4.10.1 Company Overview
      • 11.4.10.2 Financial Performance
      • 11.4.10.3 Product Benchmarking
      • 11.4.10.4 Strategic Initiatives
    • 11.4.11 Beckman Coulter, Inc.
      • 11.4.11.1 Company Overview
      • 11.4.11.2 Financial Performance
      • 11.4.11.4 Product Benchmarking
      • 11.4.11.4 Strategic Initiatives
    • 11.4.12 Bruker Corporation
      • 11.4.12.1 Company Overview
      • 11.4.12.2 Financial Performance
      • 11.4.12.3 Product Benchmarking
      • 11.4.12.4 Strategic Initiatives
    • 11.4.13 Immunexpress, Inc.
      • 11.4.13.1 Company Overview
      • 11.4.13.2 Financial Performance
      • 11.4.13.3 Product Benchmarking
      • 11.4.13.4 Strategic Initiatives
    • 11.4.14 Koninklijke Philips N.V.
      • 11.4.14.1 Company Overview
      • 11.4.14.2 Financial Performance
      • 11.4.14.3 Product Benchmarking
      • 11.4.14.4 Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제